Amerikanische Gesellschaft für Hirudotherapie

Bivalirudin for pediatric procedural anticoagulation: a narrative review

Narrative review published in Anesthesia and Analgesia (2019)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungZaleski KL et al. · Anesthesia and analgesia, 2019

Abstract

Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ), a direct thrombin inhibitor, has found increasing utilization as a heparin alternative in the pediatric population, most commonly for the treatment of thrombosis secondary to heparin-induced thrombocytopenia. Due to the relative rarity of heparin-induced thrombocytopenia as well as the lack of Food and Drug Administration-approved indications in this age group, much of what is known regarding the pharmacokinetics and pharmacodynamics of bivalirudin in this population has been extrapolated from adult data. This narrative review will present recommendations regarding the use of bivalirudin for procedural anticoagulation in the pediatric population based on the published literature.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAdolescentAge FactorsAntithrombinsBlood CoagulationCardiac CatheterizationCardiac Surgical ProceduresCardiopulmonary BypassChildChild, PreschoolDrug Administration ScheduleDrug Dosage CalculationsHemorrhage

Zusammenfassung

Comprehensive review of bivalirudin pharmacology, dosing strategies, and procedural use in pediatric cardiac catheterization and cardiopulmonary bypass — emphasizing HIT and heparin-resistance contexts.

Warum dies für die Hirudotherapie relevant ist

This narrative review examines the use of bivalirudin—a direct thrombin inhibitor—for procedural anticoagulation in the pediatric population, most commonly for thrombosis secondary to heparin-induced thrombocytopenia, and provides practice recommendations based on the published literature. The authors note that much of the pharmacokinetic and pharmacodynamic understanding of bivalirudin in children has been extrapolated from adult data, given the rarity of HIT and the absence of FDA-approved pediatric indications. For ASH's domain, this review has no defensible connection to hirudotherapy or the leech secretome—the abstract describes bivalirudin as a direct thrombin inhibitor used as a heparin alternative without any mention of leeches, hirudin, or molecular derivation from leech-derived compounds.

Zitation

Bivalirudin for pediatric procedural anticoagulation: a narrative review.

Zaleski KL et al. · Anesthesia and analgesia, 2019

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsBivalirudinAnticoagulation CompoundsHemostasisCardiovascularCardiologyPediatricsOtolaryngologyPulmonology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.